NXGL NEXGEL INC

NEXGEL to Report First Quarter 2023 Financial Results on May 15th

NEXGEL to Report First Quarter 2023 Financial Results on May 15th

Management will host a conference call at 4:30 P.M. ET on the same day

LANGHORNE, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter ended March 31, 2023, after the market closes on May 15, 2023.

Following the release of its financial and operating results, the Company will host a conference call at 4:30 P.M. ET on May 15, 2023. The conference call will be webcast live and can be accessed by registering on the portion of NEXGEL’s Investor Relations website. The webcast will be archived for approximately 90 days.

NEXGEL First Quarter 2023 Financial Results Conference Call

Date: May 15, 2023

Time: 4:30 P.M. ET

Live Call: or

Webcast:

For interested individuals unable to join the conference call, a replay will be available through May 22, 2023, at or . Participants must use the following code to access the replay of the call: 37834998. An archived version of the webcast will also be available on NEXGEL’s Investor Relations site: .

About NEXGEL, INC.

NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.

Investor Contacts:

Valter Pinto, Managing Director

KCSA Strategic Communications

212.896.1254

Media Contacts:

Kelly Knobeck

Director of Consumer Products



EN
09/05/2023

Underlying

NXGLNEXGEL INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEXGEL INC

 PRESS RELEASE
Free
NXGL NEXGEL INC

NEXGEL Announces Consideration Terms of Agreement to License and Acqui...

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio  Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing LANGHORNE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDA...

10h / 21m 1 EN
 PRESS RELEASE
Free
NXGL NEXGEL INC

NEXGEL Signs Definitive Agreement to License and Acquire Transformativ...

NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding ...

March 10, 2026 1 EN
 PRESS RELEASE
Free
NXGL NEXGEL INC

NEXGEL Announces Financing of $1.797 Million Relating to an Acquisitio...

NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence LANGHORNE, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the financing of $1.797 million relating to a potential acquisition targeted for the first quarter of 2026. The potential acqu...

February 10, 2026 1 EN
 PRESS RELEASE
Free
NXGL NEXGEL INC

NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis ...

NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that NexGelRx, the Company’s previously announced spin-off of select drug delivery application assets, has received strategic investments from Eric ...

December 16, 2025 1 EN
 PRESS RELEASE
Free
NXGL NEXGEL INC

NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx

NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off NEXGEL will also receive a 5% global royalty in perpetuity on products sold using its drug delivery technology LANGHORNE, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applica...

December 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch